<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935438</url>
  </required_header>
  <id_info>
    <org_study_id>476/19</org_study_id>
    <nct_id>NCT03935438</nct_id>
  </id_info>
  <brief_title>The Influence of Cardiac Rehabilitation on the Health State After ACS</brief_title>
  <acronym>CARDIO-REH</acronym>
  <official_title>The Influence of Cardiac Rehabilitation on the Health State of Patients After Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary heart disease, including acute coronary syndromes (ACS), is the leading cause of&#xD;
      death in European countries. One of the basic elements of secondary and tertiary prevention&#xD;
      of ACS is cardiac rehabilitation.&#xD;
&#xD;
      The aims of the study are evaluation of the impact of cardiac rehabilitation on health state-&#xD;
      especially on cardiovascular function parameters in patients after acute coronary syndrome&#xD;
      and evaluation of the influence of the level of gene expression and polymorphisms of genes&#xD;
      associated with ischemic heart disease on the course of cardiac rehabilitation in patients&#xD;
      after ACS.&#xD;
&#xD;
      The study will consist of a retrospective and prospective part. The retrospective part will&#xD;
      include patients who have had acute coronary syndrome in the past and then - before being&#xD;
      included in the study - have undergone cardiac rehabilitation. In the retrospective part,&#xD;
      patients enrolled in the study will not undergo cardiac rehabilitation as a part of the study&#xD;
      intervention. The prospective part will include patients who have had an acute coronary&#xD;
      syndrome in the past and will undergo cardiac rehabilitation as the study intervention.&#xD;
&#xD;
      After being included in the study, patients will undergo medical examination. Then subsequent&#xD;
      procedures will be performed: anthropometric measurements; ECG; body composition analysis by&#xD;
      bioimpedance; measurement of resting blood pressure, resting heart rate and oxygen saturation&#xD;
      of hemoglobin; pulse wave analysis; transthoracic echocardiography of the heart; 24-hour&#xD;
      blood pressure measurement by ambulatory blood pressure monitoring (ABPM); 24-hour ECG&#xD;
      recording using the Holter method; electrocardiographic exercise test on a treadmill and / or&#xD;
      a six-minute walk test or other exercise test adequate to the patient's state of health;&#xD;
      assessment of the quality of the diet; assessment of lifestyle, acceptance of disease and&#xD;
      quality of life; assessment of the psychological profile.&#xD;
&#xD;
      Subsequently patients taking part in the prospective part of the study will perform a cardiac&#xD;
      rehabilitation program.&#xD;
&#xD;
      After the cardiac rehabilitation program measurement procedures listed above will be&#xD;
      repeated.&#xD;
&#xD;
      Before and after the cardiac rehabilitation program blood samples, urine samples and hair&#xD;
      samples will be collected. Blood samples, urine samples and hair samples will also be&#xD;
      collected from patients taking part in the retrospective part of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary heart disease, including acute coronary syndromes (ACS), is the leading cause of&#xD;
      death in European countries, including Poland. In addition, it is one of the main causes of&#xD;
      disability and the number of lost years of life and the number of years of life lost in good&#xD;
      health. The costs of its treatment include not only the primary prophylaxis of cardiovascular&#xD;
      events, the treatment of cardiovascular events, the treatment of chronic conditions and&#xD;
      complications such as chronic heart failure or arrhythmia, but also the secondary and&#xD;
      tertiary prophylaxis of acute coronary syndromes.&#xD;
&#xD;
      One of the basic elements of secondary and tertiary prevention of ACS is cardiac&#xD;
      rehabilitation. It should be implemented as soon as possible after the ACS and be part of a&#xD;
      comprehensive, planned and systematic care of the patient after ACS. The beneficial effect of&#xD;
      cardiac rehabilitation on the cardiovascular system, lipid and carbohydrate metabolism and&#xD;
      physical performance has been demonstrated in a way that does not raise any doubts. However,&#xD;
      in the light of the growing epidemic of civilization diseases such as excessive body mass,&#xD;
      diabetes, dyslipidemia, hypertension and other cardiometabolic disorders, it is necessary to&#xD;
      conduct high-quality research on the development of the most effective cardiac rehabilitation&#xD;
      programs, so as to maximize their beneficial effect on patients' health.&#xD;
&#xD;
      The aims of the study are:&#xD;
&#xD;
        1. Evaluation of the impact of cardiac rehabilitation on selected anthropometric,&#xD;
           biochemical, mineral parameters, body composition parameters, physical fitness&#xD;
           parameters and cardiovascular function parameters in patients after acute coronary&#xD;
           syndrome.&#xD;
&#xD;
        2. Assessment of lifestyle, acceptance of disease, quality of life, diet and psychological&#xD;
           profile and the influence of these factors on the course of cardiac rehabilitation in&#xD;
           patients after acute coronary syndrome.&#xD;
&#xD;
        3. Evaluation of the influence of the level of gene expression and polymorphisms of genes&#xD;
           associated with ischemic heart disease and predisposing conditions (including excessive&#xD;
           body weight, hypertension, lipid and carbohydrate disorders, impaired vascular&#xD;
           endothelial function) on the course of cardiac rehabilitation in patients after acute&#xD;
           coronary syndrome and searching for new genes that may affect the course of cardiac&#xD;
           rehabilitation in this group of patients.&#xD;
&#xD;
      Research hypotheses:&#xD;
&#xD;
        1. Cardiac rehabilitation has a positive effect on selected anthropometric, biochemical,&#xD;
           mineral parameters, body composition parameters, physical fitness parameters and&#xD;
           cardiovascular function parameters in patients after acute coronary syndrome.&#xD;
&#xD;
        2. Lifestyle, acceptance of disease, quality of life, diet and psychological profile have a&#xD;
           significant impact on the course of cardiac rehabilitation in patients after acute&#xD;
           coronary syndrome.&#xD;
&#xD;
        3. The level of expression and gene polymorphism of genes associated with ischemic heart&#xD;
           disease and predisposing conditions (including excessive body weight, hypertension,&#xD;
           lipid and carbohydrate disorders, impaired vascular endothelial function) have a&#xD;
           significant impact on the course of cardiac rehabilitation in patients after acute&#xD;
           coronary syndrome.&#xD;
&#xD;
      The study will consist of a retrospective and prospective part. The retrospective part will&#xD;
      include patients who have had acute coronary syndrome in the past and then - before being&#xD;
      included in the study - have undergone cardiac rehabilitation. In the retrospective part,&#xD;
      patients enrolled in the study will not undergo cardiac rehabilitation as a part of the study&#xD;
      intervention. In contrast, the prospective part will include patients who have had an acute&#xD;
      coronary syndrome in the past and will undergo cardiac rehabilitation as the study&#xD;
      intervention.&#xD;
&#xD;
      About 200 women and men aged 18 to 99 are planned to be included in the study.&#xD;
&#xD;
      After being included in the study, patients will undergo medical examination and their&#xD;
      medical documentation will be collected, analyzed, copied and archived. Then subsequent&#xD;
      procedures will be performed:&#xD;
&#xD;
        -  anthropometric measurements (body weight, height, hip, waist, neck circumference&#xD;
           measurement)&#xD;
&#xD;
        -  ECG - electrocardiography&#xD;
&#xD;
        -  non-invasive analysis of the body composition by bioimpedance&#xD;
&#xD;
        -  non-invasive measurement of resting blood pressure, resting heart rate and oxygen&#xD;
           saturation of hemoglobin&#xD;
&#xD;
        -  non-invasive pulse wave analysis&#xD;
&#xD;
        -  non-invasive transthoracic echocardiography of the heart&#xD;
&#xD;
        -  non-invasive 24-hour blood pressure measurement by ABPM&#xD;
&#xD;
        -  non-invasive 24-hour ECG recording using the Holter method&#xD;
&#xD;
        -  non-invasive electrocardiographic exercise test on a treadmill and / or a six-minute&#xD;
           walk test or other exercise test adequate to the patient's state of health; these tests&#xD;
           will always be preceded by a detailed medical qualification&#xD;
&#xD;
        -  assessment of the quality of the diet&#xD;
&#xD;
        -  assessment of lifestyle, acceptance of disease and quality of life&#xD;
&#xD;
        -  assessment of the psychological profile&#xD;
&#xD;
      Subsequently patients taking part in the prospective part of the study will perform a cardiac&#xD;
      rehabilitation program.&#xD;
&#xD;
      After the cardiac rehabilitation program measurement procedures listed above (anthropometric&#xD;
      measurements; ECG; non-invasive analysis of the body composition by bioimpedance;&#xD;
      non-invasive measurement of resting blood pressure, resting heart rate and oxygen saturation&#xD;
      of hemoglobin; non-invasive pulse wave analysis; non-invasive transthoracic echocardiography&#xD;
      of the heart; non-invasive 24-hour blood pressure measurement by ABPM; non-invasive 24-hour&#xD;
      ECG recording using the Holter method; non-invasive electrocardiographic exercise test;&#xD;
      assessment of the quality of the diet; assessment of lifestyle, acceptance of disease and&#xD;
      quality of life; assessment of the psychological profile) will be repeated.&#xD;
&#xD;
      Before and after the cardiac rehabilitation program blood samples, urine samples and hair&#xD;
      samples will be collected. Blood samples, urine samples and hair samples will also be&#xD;
      collected from patients taking part in the retrospective part of the study.&#xD;
&#xD;
      After data collection statistical analyses will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulse wave velocity (PWV) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Pulse wave velocity I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PWV II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Pulse wave velocity II</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aortic pressure (AP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Aortic pressure I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Aortic pressure II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass (BM) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Body mass I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BM II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Body mass II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body height (BH) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Body height I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BH II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Body height II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Body mass index I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Body mass index II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference (WC) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Waist circumference I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WC II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Waist circumference II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference (HC) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Hip circumference I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HC II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Hip circumference II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck circumference (NC) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Neck circumference I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NC II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Neck circumference II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fat percentage (TF%) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Total fat percentage I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TF% II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Total fat percentage II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure (SBP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Systolic blood pressure I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Systolic blood pressure II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure (DBP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Diastolic blood pressure I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Diastolic blood pressure II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Heart rate I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HR II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Heart rate II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood oxygen saturation (SO2) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood oxygen saturation I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SO2 II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood oxygen saturation II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction (EF) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Ejection fraction I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EF II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Ejection fraction II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure monitoring- systolic blood pressure (ABPM SBP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Ambulatory blood pressure monitoring- systolic blood pressure I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABPM SBP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Ambulatory blood pressure monitoring- systolic blood pressure II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure monitoring- diastolic blood pressure (ABPM DBP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Ambulatory blood pressure monitoring- diastolic blood pressure I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABPM DBP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Ambulatory blood pressure monitoring- diastolic blood pressure II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic equivalent (MET) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Metabolic equivalent I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MET II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Metabolic equivalent II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance in 6-minutes walk (6MW-D) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Distance in 6-minutes walk I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MW-D II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Distance in 6-minutes walk II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartate aminotransferase (AST) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of aspartate aminotransferase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of aspartate aminotransferase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine aminotransferase (ALT) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of alanine aminotransferase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of alanine aminotransferase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total bilirubin (TB) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of total bilirubin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of total bilirubin II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>indirect bilirubin (IB) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of indirect bilirubin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IB II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of indirect bilirubin II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>direct bilirubin (DB) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of direct bilirubin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of direct bilirubin II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gamma-glutamyltransferase (GGTP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of gamma-glutamyltransferase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GGTP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of gamma-glutamyltransferase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol (TCH) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of total cholesterol I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCH II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of total cholesterol II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low density lipoprotein (LDL) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of low density lipoprotein I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of low density lipoprotein II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high density lipoprotein (HDL) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of high density lipoprotein I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of high density lipoprotein II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides (TG) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of triglycerides I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of triglycerides II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein A (ApoA) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of apolipoprotein A I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoA II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of apolipoprotein A II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin (INS) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of insulin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INS II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of insulin II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose (GLU) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of glucose I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLU II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of glucose II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine (CREA) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of creatinine I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CREA II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of creatinine II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of C-reactive protein I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of C-reactive protein II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adropin (ADR) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of adropin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADR II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of adropin II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neopterin (NEOPT) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of neopterin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEOPT II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of neopterin II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal natriuretic propeptide type B (NTpro-BNP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of N-terminal natriuretic propeptide type B I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTpro-BNP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of N-terminal natriuretic propeptide type B II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>magnesium (Mg) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of magnesium I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mg II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of magnesium II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>homocysteine (Hcy) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of homocysteine I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hcy II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of homocysteine II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>troponin (TROP) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of troponin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TROP II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of troponin II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 6 (IL6) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of interleukin 6 I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL6 II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of interleukin 6 II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor necrosis factor (TNF) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of tumor necrosis factor I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of tumor necrosis factor II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular endothelial growth factor (VEGF) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of vascular endothelial growth factor I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of vascular endothelial growth factor II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leptin (LPT) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Blood concentration of leptin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPT II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Blood concentration of leptin II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF polymorphism</measure>
    <time_frame>At baseline</time_frame>
    <description>Polymorphism of the VEGF gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentration of magnesium (U-Mg) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Urine concentration of magnesium I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>U-Mg II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Urine concentration of magnesium II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hair content of magnesium (H-Mg) I</measure>
    <time_frame>At baseline</time_frame>
    <description>Hair content of magnesium I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H-Mg II</measure>
    <time_frame>After intervention completion- an average of 2 weeks from baseline</time_frame>
    <description>Hair content of magnesium II</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiac Rehabilitation</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients after ACS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients after acute coronary syndrome undergoing cardiac rehabilitation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac rehabilitation</intervention_name>
    <description>The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.</description>
    <arm_group_label>Patients after ACS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent in writing&#xD;
&#xD;
          -  Coronary heart disease, a state after an acute coronary syndrome&#xD;
&#xD;
          -  Female or male&#xD;
&#xD;
          -  Age 18 - 99 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active neoplastic disease&#xD;
&#xD;
          -  Alcohol abuse, drug abuse&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Other conditions that in the opinion of researchers may pose any risk to the patient&#xD;
             during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian Skrypnik, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznan University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damian Skrypnik, MD; PhD</last_name>
    <phone>+48798394812</phone>
    <email>damian.skrypnik@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paweł Bogdański, Prof.</last_name>
    <phone>+48502335001</phone>
    <email>pawelbogdanski73@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolska</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian Skrypnik, MD, PhD</last_name>
      <phone>+48798394812</phone>
      <email>damian.skrypnik@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Paweł Bogdański, Prof.</last_name>
      <phone>+48502335001</phone>
      <email>pawelbogdanski73@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Damian Skrypnik</investigator_full_name>
    <investigator_title>Principal Investigator and Study Manager; Doctor of Medicine</investigator_title>
  </responsible_party>
  <keyword>cardiac rehabilitation</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>anthropometric parameters</keyword>
  <keyword>physical efficiency</keyword>
  <keyword>cardiovascular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The decision of individual participant data (IPD) sharing may be changed in the future.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

